GIBSON DUNN

Gibson Dunn Advises Galecto, Inc. on Establishing At-the-Market Facility for Sale of up to $150 Million of Common Stock

Firm News | February 12, 2026

Gibson Dunn represented Galecto, Inc. in establishing an at-the-market facility for the sale of up to $150 million of shares of its common stock.

Galecto is a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers.

Gibson Dunn regularly advises biopharmaceutical companies on at-the-market equity offerings and other capital markets transactions.

The Gibson Dunn team included Ryan Murr, Branden Berns, Melanie Neary, Nicholas Linke, Lauren Navarro, and Anika Gidwani.

Related People

Ryan A. Murr

Branden C. Berns

Melanie E. Neary

Nicholas G. Linke

Lauren Navarro

Anika Gidwani

Related Capabilities

Capital Markets

Life Sciences

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**